The benefits of hydroxychloroquine being investigated in multi-site clinical trial launching in April

Researchers are investigating whether hydroxychloroquine – a commonly used anti-malarial and autoimmune drug – can prevent COVID-19.

A multi-site clinical trial, led by the University of Washington Department of Global Health/International Clinical Research Center (ICRC)  in collaboration with NYU Grossman School of Medicine, aims to definitively determine whether hydroxychloroquine can prevent transmission in people exposed to the virus.

Paul Drain—an Associate Professor in the Department of Global Health, Medicine and Epidemiology at the University of Washington—and his research team have received a new grant from the CoMotion Innovation Gap Fund, a program intended to help bridge the gap between academic research grants and the level of development needed to obtain investment. Drain’s project is titled “Rapid test for measuring adherence to antiretroviral therapy and pre-exposure prophylaxis”.  

The University of Washington/Fred Hutch Center for AIDS Research (CFAR) recently announced the recipients of their International Infrastructure Awards. Geoffrey Gottlieb (Adjunct Professor of Global Health), John Kinuthia (Affiliate Associate Professor), Rose Bosire (Clinical Research Scientist/Global Health Fellow), and Sylvia LaCourse (Assistant Professor) each received awards.

As lockdowns sweep the country and people prepare to work from home for months, many are wondering whether springtime’s warmer temperatures will provide much-needed relief from the coronavirus. Others, including President Donald Trump, have made the case that it’s a certainty.